Compare Sibanye Stillwater Ltd (SBSW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs TG Therapeutics Inc — how do they compare? Sibanye Stillwater Ltd trades at $8.59 (market cap $5.66B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SBSW | TGTX | |
|---|---|---|
Market Cap | $5.66B | $8.26B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $59.06 |
52-Week Low | $7.27 | $26.39 |
Enterprise Value | $7.28B | $8.50B |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $8.59, up 7.38% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $7.30B in 2024 despite $112.13B revenue, though 2025 projections show improved EBITDA of $21.4B. Analyst consensus is mixed with 42.9% buy ratings and a $14.25 price target, representing 66% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with deep value characteristics (P/E 4.76, P/S 0.72) but faces significant execution risks amid negative ROE and ROA. Key catalysts include management's debt reduction targets and operational improvements, while commodity price volatility remains a major headwind for the mining company.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
